BTIG raised the firm’s price target on Xtant Medical to $3 from $2 and keeps a Buy rating on the shares. The company’s Q1 results were “encouraging” and driven by strength from the legacy Surgalign portfolio, the analyst tells investors in a research note. Now two-to-three quarters since the acquisition, Surgalign is contributing solidly in the hardware segment while Xtant has improved stem cell supply dynamics, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XTNT:
- Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
- Xtant Medical’s Earnings at Risk: The Unhedged Perils of Currency Fluctuations
- Xtant Medical sees FY24 revenue $112M-$116M
- Xtant Medical reports Q4 EPS (3c) vs (2c) last year
- Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024